Astrazeneca plc, of London, said the FDA accepted for filing the new drug application for Iressa (gefitinib) as a targeted monotherapy for first-line advanced or metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer, as identified through a companion diagnostic test.